1. Pink Sheet

Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care

 
• By Sarah Karlin-Smith and Jinghong Chen

In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.

road that splits in two directions with one direction leading toward "generic brand" and one direction leading toward "name brand"
Incentives in the US health care system make it hard for biosimilars to make inroads on brands used in the outpatient setting • Source: Shutterstock

AbbVie Inc.’s Humira lost 2% of market share to biosimilars in the US in 2023, the first year the blockbuster drug faced direct copycat competition.

Key Takeaways
  • Humira’s continued strong formulary position in its second year facing biosimilar competition is discouraging health policy experts and generic executives alike about the prospects for future biosimilar...

2024 isn’t shaping up to be a whole lot worse for the biologic – two of the three major pharmacy benefits managers are keeping the brand at parity with adalimumab...

More from Biosimilars

More from Biosimilars & Generics